Vedanta Biosciences reveals Phase 2 VE303 results - PharmaTimes Study highlights VE303's potential in reducing recurrent CDI

#gastroenterology #VedantaBiosciences #VE303 #recurrentCDI #Phase2CONSORTIUMstudy #recurrentClostridioidesdifficileinfection #rCDI #rCDIprevention #CDIrecurrence #VE303organisms #VE303mechanisms #microbiomerestoration #microbiome #RESTORATiVE303 #CDIresistance
pharmatimes.com/news/vedanta...